Skip to main content
Top
Published in: Diabetologia 12/2019

Open Access 01-12-2019 | Insulins | Article

Circulating metabolites and the risk of type 2 diabetes: a prospective study of 11,896 young adults from four Finnish cohorts

Authors: Ari V. Ahola-Olli, Linda Mustelin, Maria Kalimeri, Johannes Kettunen, Jari Jokelainen, Juha Auvinen, Katri Puukka, Aki S. Havulinna, Terho Lehtimäki, Mika Kähönen, Markus Juonala, Sirkka Keinänen-Kiukaanniemi, Veikko Salomaa, Markus Perola, Marjo-Riitta Järvelin, Mika Ala-Korpela, Olli Raitakari, Peter Würtz

Published in: Diabetologia | Issue 12/2019

Login to get access

Abstract

Aims/hypothesis

Metabolomics technologies have identified numerous blood biomarkers for type 2 diabetes risk in case−control studies of middle-aged and older individuals. We aimed to validate existing and identify novel metabolic biomarkers predictive of future diabetes in large cohorts of young adults.

Methods

NMR metabolomics was used to quantify 229 circulating metabolic measures in 11,896 individuals from four Finnish observational cohorts (baseline age 24–45 years). Associations between baseline metabolites and risk of developing diabetes during 8–15 years of follow-up (392 incident cases) were adjusted for sex, age, BMI and fasting glucose. Prospective metabolite associations were also tested with fasting glucose, 2 h glucose and HOMA-IR at follow-up.

Results

Out of 229 metabolic measures, 113 were associated with incident type 2 diabetes in meta-analysis of the four cohorts (ORs per 1 SD: 0.59–1.50; p< 0.0009). Among the strongest biomarkers of diabetes risk were branched-chain and aromatic amino acids (OR 1.31–1.33) and triacylglycerol within VLDL particles (OR 1.33–1.50), as well as linoleic n-6 fatty acid (OR 0.75) and non-esterified cholesterol in large HDL particles (OR 0.59). The metabolic biomarkers were more strongly associated with deterioration in post-load glucose and insulin resistance than with future fasting hyperglycaemia. A multi-metabolite score comprised of phenylalanine, non-esterified cholesterol in large HDL and the ratio of cholesteryl ester to total lipid in large VLDL was associated with future diabetes risk (OR 10.1 comparing individuals in upper vs lower fifth of the multi-metabolite score) in one of the cohorts (mean age 31 years).

Conclusions/interpretation

Metabolic biomarkers across multiple molecular pathways are already predictive of the long-term risk of diabetes in young adults. Comprehensive metabolic profiling may help to target preventive interventions for young asymptomatic individuals at increased risk.
Appendix
Available only for authorised users
Literature
6.
15.
go back to reference Pitkänen N, Juonala M, Rönnemaa T et al (2016) Role of conventional childhood risk factors versus genetic risk in the development of type 2 diabetes and impaired fasting glucose in adulthood: the Cardiovascular Risk in Young Finns Study. Diabetes Care 39(8):1393–1399. https://doi.org/10.2337/dc16-0167 CrossRefPubMed Pitkänen N, Juonala M, Rönnemaa T et al (2016) Role of conventional childhood risk factors versus genetic risk in the development of type 2 diabetes and impaired fasting glucose in adulthood: the Cardiovascular Risk in Young Finns Study. Diabetes Care 39(8):1393–1399. https://​doi.​org/​10.​2337/​dc16-0167 CrossRefPubMed
Metadata
Title
Circulating metabolites and the risk of type 2 diabetes: a prospective study of 11,896 young adults from four Finnish cohorts
Authors
Ari V. Ahola-Olli
Linda Mustelin
Maria Kalimeri
Johannes Kettunen
Jari Jokelainen
Juha Auvinen
Katri Puukka
Aki S. Havulinna
Terho Lehtimäki
Mika Kähönen
Markus Juonala
Sirkka Keinänen-Kiukaanniemi
Veikko Salomaa
Markus Perola
Marjo-Riitta Järvelin
Mika Ala-Korpela
Olli Raitakari
Peter Würtz
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 12/2019
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-019-05001-w

Other articles of this Issue 12/2019

Diabetologia 12/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.